## **AMENDMENT TO CLAIMS**

The listing of claims will replace all prior versions and listing of claims in the application:

## **Listing of Claims:**

Claim 1-12: (previously cancelled).

Claim 13 (currently amended): A method of treating airway and gastrointestinal disorders, said method comprising administering to a mammalian patient in need of such treatment a pharmaceutical composition which comprises therapeutically effective amounts of a compound of claim 16. Claim 14 (previously cancelled).

Claim 15 (currently amended): A method of preparing a pharmaceutical composition for treating airway and gastrointestinal disorders, said method comprising bringing into intimate contact a compound of claim 16 and a pharmaceutically acceptable carrier.

Claim 16 (currently amended): A compound exhibiting H<sub>3</sub> antagonist activity, or enantiomers, stereoisomers and tautomers of said compound, or pharmaceutically acceptable salts or solvates of said compound, said compound being selected from the compounds with structures listed below:

Claim 17 (previously amended): A compound exhibiting both H<sub>1</sub> and H<sub>3</sub> antagonist activity, or enantiomers, stereoisomers and tautomers of said compound, or pharmaceutically acceptable salts or solvates of said compound, said compound being selected from the compounds with structures listed below:

Claim 18 (currently amended): A pharmaceutical composition for treating airway and gastrointestinal disorders, said composition comprising therapeutically effective amount of a compound of claim 16 or claim 17 and a pharmaceutically acceptable carrier.

Claims 19-21 (previously cancelled).

Claim 22 (currently amended): A method of treating airway and gastrointestinal disorders, said method comprising administering to a mammalian patient in need of such treatment a pharmaceutical composition which comprises therapeutically effective amounts of a compound of claim 17. Claim 23 (currently amended): A method of preparing a pharmaceutical composition for treating airway and gastrointestinal disorders, said method comprising bringing into intimate contact a compound of claim 17 and a pharmaceutically acceptable carrier.